LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


First Inhaled Nanobody Achieves Proof-of-Concept with Successful Phase 1 Results


« Back to News


-ALX-0171 is a Potential First-in-Class Therapy-

-Tremendous Potential in Multiple Lung Diseases-


Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx

Ablynx NV (Euronext Brussels: ABLX) just reported successful Phase 1 results for ALX-0171, the first inhaled nanobody. Delivering therapeutic antibodies to the lung via inhalation has proven unsuccessful due to serious immunogenicity concerns. In this study, ALX-0171 was well tolerated and did not exhibit any immunogenicity effects typically associated with antibodies.

Phase 1 Data Provides Proof-of-Concept for Inhaled Nanobodies. Ablynx just reported Phase 1 data that suggests that ALX-0171 could be successfully administered directly into the lung in a clinical trial setting. This confirms its potential as a first-in-class therapy to treat RSV infections. More importantly, this confirms the potential for the Nanobody platform to develop therapeutic compounds that can be delivered directly into the lung. Beyond RSV, the ability to deliver Nanobodies directly to the lung has broad implications for the potential of Ablynx’s platform to generate Nanobodies treating a variety of lung diseases, including Asthma and COPD. These potential implications address very large market opportunities that Ablynx could be poised to benefit from.

ALX-0171, is a trivalent molecule specifically designed by Ablynx for direct lung delivery via nebulizer to treat respiratory syncytial virus (RSV) infections. The specific structure of the Nanobody lends a small size, robustness, and stability that makes it possible for direct lung delivery. Direct lung delivery is a more convenient route of administration for treating a variety of lung diseases that scientists have not been able to successfully achieve with antibodies.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design